StockNews.AISignal intelligence
Contineum Therapeutics, Inc. Class A Common Stock · NASDAQ · Healthcare
Browse public CTNM signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Contineum Therapeutics fell after Phase 2 MOONLIGHT-1 failed to meet the primary endpoint for JNJ-5120/PIPE-307 in major depressive disorder. Johnson & Johnson is reviewing the data, including exploratory endpoints, to determine next steps under the license. While the longer-term setup looks constructive, near-term action will hinge on reclaiming the 50-day line and key supports.
View signal analysisCTNM's Phase 2 VISTA trial for PIPE-307 showed no efficacy. The trial met safety metrics but missed primary/secondary endpoints. RBC Capital lowered CTNM's price forecast from $25 to $22. CTNM's stock dropped 13.26% following the negative trial results. Future prospects depend on PIPE-791 in idiopathic pulmonary fibrosis.
View signal analysis